Type 2 diabetes mellitus (T2DM) is associated with a two-to four-fold increased risk of developing cardiovascular disease (CVD) and microvascular complications, which may already be present before diagnosis. It is, therefore, important to detect people with an increased risk of T2DM at an early stage. In order to identify individuals with so-called 'pre-diabetes', comprising impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), current guidelines have developed definitions based on fasting plasma glucose, two-hour glucose concentrations and haemoglobin A1c. Subjects with pre-diabetes are at an increased risk of developing T2DM and CVD. This elevated risk seems similar according to the different criteria used to define pre-diabetes. The risk of progression to T2DM or CVD does, however, depend on other risk factors such as sex, body mass index and ethnicity. Based on the risk factors to develop T2DM, many risk assessment models have been developed to identify those at highest risk. These models perform well to identify those at risk and could be used to initiate preventive interventions. Many studies have shown that lifestyle modification and metformin are effective in preventing the development of T2DM, although lifestyle modification seems to have a more sustainable effect. In addition, lifestyle modification seems more effective in those with IGT than those with IFG. In this review, we will describe the different definitions used to define pre-diabetes, progression from prediabetes to T2DM or other vascular complications, risk factors associated with progressions and the management of progression to T2DM, ending with clinical recommendations.
Introduction
Type 2 diabetes mellitus (T2DM) is a societal burden and associated with major complications, such as blindness, kidney failure, lower-limb amputation and cardiovascular disease (CVD). 1 The societal burden of T2DM has increased in the past decades due to population ageing and increasing prevalence of underlying risk factors, such as obesity, increased sedentary activity and unhealthy diet. Even though T2DM can be treated and its consequences avoided or delayed with diet, physical activity, medication and regular screening and treatment of complications, 2, 3 to halt the diabetes epidemic, we need to target those at risk for developing T2DM. This is especially important since macrovascular complications may already be present well before the official diagnosis of T2DM. 4 The diagnosis of T2DM is based on measurements of fasting glucose concentrations, two-hour plasma glucose concentrations during an oral glucose tolerance test (OGTT) and/or haemoglobin A1c (HbA1c) concentrations. Lower thresholds of these measurements are used to define early stages of the disease. People at early stages of dysglycaemic conditions could be at risk of developing T2DM and, thus, targeted with preventive interventions. These early stages are often referred to as pre-diabetes, although the use of this term is heavily debated. Other names for pre-diabetes have been suggested, such as 'intermediate hyperglycaemia' or 'high risk state of developing diabetes'. However, for simplicity, we will use the term pre-diabetes in this review.
In this review, we will describe the different definitions used to define pre-diabetes, progression from pre-diabetes to T2DM or other vascular complications, risk factors associated with progression and cardiovascular complications, the management of progression to T2DM and ending with clinical recommendations.
Definition of pre-diabetes
'Pre-diabetes' is the general term that refers to an intermediate stage between normal glucose tolerance (NGT) and overt T2DM, and individuals with pre-diabetes are at high risk to develop T2DM. 5 There are two frequently used definitions for pre-diabetes, one from the American Diabetes Association (ADA) and another from the International Expert Committee and World Health Organization (WHO). Both definitions are based on measurements of fasting glucose concentrations, two-hour plasma glucose concentrations during an OGTT and/or HbA1c concentrations. The latter was only recently included in the definition. However, it has been debated how valuable this is in clinical practice. 6, 7 HbA1c does not diagnose all people with T2DM, and the only way to identify impaired glucose tolerance (IGT) is via an OGTT. 8 Combinations of different measurements define several forms of pre-diabetes. Please see Table 1 for the exact cut-off points, but, in short, pre-diabetes is defined as: 1) Isolated IGT -a person having high values after a 75 -g OGTT; 2) Isolated impaired fasting glucose (IFG) -a person having high fasting plasma glucose values; 3) The combination of IGT and IFG; 4) High-risk HbA1c concentrations. 9
Prevalence
The prevalence of pre-diabetes obviously depends on the age range of the population studied, with older people having a higher prevalence, as well as the definition used with a higher prevalence when using the ADA criteria as a result of the difference in cut-off values (see Table 1 ), compared with the WHO criteria. For example, in the population-based cohort of participants aged 60þ years in the Hoorn study, 10 the prevalence of isolated IFG was 33.2% (95% confidence interval (CI) 30-36) based on the ADA criteria and 10.1% (CI 9-12) based on the International Expert Committee and WHO criteria. The pre-diabetes definition based on multiple criteria shows that the term 'pre-diabetes' represents several groups of individuals, all with a distinct pathophysiologic aetiology, with some predominantly associated with obesity and insulin resistance, while others with loss of beta-cell function as the primary abnormality. 9 These distinct pathophysiologic pathways are further illustrated by limited overlap between the different measurement criteria. 11 A recent elegant meta-analysis by Barry et al. (2017) 11 showed that when combining data from the only five studies in middle-aged participants that used both the WHO and ADA definition, the overall overlap prevalence of pre-diabetes was 27%. Of those with abnormal results, 4.7% had isolated IFG, 24.4% had isolated IGT, 47.8% had isolated high HbA1c and only 3.9% had a combination of IGT, IFG and high HbA1c. Applying the ADA criteria to this same compiled cohort of five studies, the prevalence of pre-diabetes was 49%, with 71% of these identified by raised HbA1c concentrations alone. In addition, only 8.7% of the participants had a combination of IGT, IFG and high HbA1c. 11 Moreover, the different criteria only showed limited overlap, which may indicate that, indeed, people with different pathophysiology were identified.
The recent inclusion of HbA1c as a criterion for T2DM has led to some discussion, mainly because this results in a higher prevalence of pre-diabetes and T2DM. In addition, it is not entirely known whether people identified with these criteria are, indeed, at increased risk to develop T2DM or its cardiovascular complications. One of its limitations is that it does not predict for future CVD events, at least not in people with coronary arterial disease. 12 The superiority of a two-hour OGTT was also shown in the DECODE study. 4, 13 . The term 'pre-diabetes' has been criticized, mainly because approximately 30% of people with prediabetes will not progress to T2DM. 14 In the following section, we will elaborate on whether pre-diabetes also predicts progression to T2DM.
Progression of pre-diabetes to type 2 diabetes
Currently, a topic of debate is which of the diabetes parameters, being fasting glucose, 2 h OGTT or HbA1c, best predicts who will develop T2DM in the upcoming years and who will not. Results from a recent study including 10,796 individuals (aged >20 years) with pre-diabetes (according to the IFG-ADA and/or HbA1c-ADA criteria), showed that approximately 70% developed T2DM within 10 years. 15 However, as a result of the lower cut-off points for pre-diabetes when using the ADA criteria, not only the prevalence differs depending on the definition used, but also the incidence of progression to T2DM. Using the WHO criteria, results of the Rotterdam Study, including data of 10,050 participants (mean age 65.2 years (9.8 standard deviation (SD)) with a follow-up of up to 14.7 years, showed that a lifetime risk (calculated at index age 45, 55, 65, 75 and 85 years) to progress from pre-diabetes to T2DM of 74.0% (95% CI, 68-81) was found in individuals aged 45 years. 16 Obviously, incidence T2DM rates also depend on the definition used. This is nicely illustrated by a meta-analysis of 70 studies by Morris et al. (2013) . 17 This meta-analysis showed a pooled incidence rate of 35.6 (15-83) per 1000 person-years for the HbA1c criteria, which was non-significantly lower than WHO-defined IFG (34 studies, 47.4 (37-60)), IGT (46 studies, 45.5 (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) ) and IFG plus IGT (15 studies, 70.4 (54-90)). 17 Furthermore, not only the definition of pre-diabetes seems to be important, but also the starting level of fasting glucose concentrations. In a simulation model, it was estimated that targeted intervention with a reduction of 0.6 mmol/mol (10 mg/dL) glucose and with 25% treatment adherence would result in a 7.6% reduction in progression to T2DM in a group with fasting glucose concentrations between 6.1 and 6.7 mmol/L (110-119 mg/dL). A reduction in progression of 15% would be possible with 50% treatment adherence, while in the group with IGF levels of 6.7 mmol/L (120 mg/dL) the reduced progression to T2DM was estimated at 3.0% with 25% treatment adherence, and 6.0% with 50% treatment adherence. 15 This is relevant information for preventive strategies and resource allocation.
Aside from which pre-diabetes definition is to be used and levels of fasting glucose concentration, several other factors seem to affect risk for progression from prediabetes to T2DM. This is shown in the aforementioned Rotterdam Study, which showed that lifetime risks of progression from pre-diabetes to T2DM increased by body mass index (BMI) strata (normal weight, overweight, obesity) and waist circumference strata. Furthermore, the age of onset of pre-diabetes was about 10 years later for adults within the normal weight strata, compared with those in the obesity strata. 16 Another reported risk factor for progression to T2DM is ethnicity; Asians adults have a higher fiveyear risk of progression to T2DM within five years (incidence ratio (IR) ¼ 1.75; 95% CI, 1.2-2.6), compared with Caucasian after adjusting for BMI and other demographic characteristics. 15 Finally, differences for the time to progress from pre-diabetes to T2DM are reported by sex. On average, men have pre-diabetes for 8.5 years and women for 10.3 years before they develop T2DM (aged 25-85 years). 18 In addition, recent results from the Bogalusa Heart Study (mean age (SD) at first examination 9.4 (3.1) years) 19 showed that women had a greater change in BMI, total cholesterol, low-density lipoprotein cholesterol and fasting plasma glucose during the period of progression to T2DM than men. 19 Thus, it seems that the excess risk for progression from pre-diabetes to T2DM is multifactorial, which should be considered for preventive strategies.
Risk factors for CVD in pre-diabetes
Next to an increased risk of developing T2DM, prediabetes may also be associated with an increased risk of CVD. Although evidence exists that pre-diabetes increases the risk of CVD by 20%, it is less clear whether pre-diabetes directly causes CVD or whether it is mediated through known CVD risk factors, such as dyslipidaemia and hypertension. Again, as for the prevalence and incidence of progression to T2DM, risk of CVD also depends on the definition used for pre-diabetes. Individuals diagnosed with pre-diabetes based on the ADA criteria will, on average, be at lower risk of diabetes and CVD than individuals with WHO-defined pre-diabetes. 20 Results from the AusDiab study showed that individuals with prediabetes according to the IFG definition had a 2.5 (1.2-5.1)-fold higher relative risk (RR) of CVD morbidity and mortality than NGT, and those according to the IGT definition, only a 1.2-fold (0.7-2.0) increased risk of CVD.
On the contrary, the opposite findings were reported by the DECODE study and a systematic review, including 1,611,339 individuals and a median follow-up duration of 9.5 years. 4, 13 They showed that compared with NGT, pre-diabetes (according to IFG-ADA, IFG-WHO, IGT, HbA1c-ADA or HbA1c-National Institute for Health and Care Excellence (NICE) criteria) was associated with an increased risk of composite CVD, irrespective of the definition used (RR between 1.13 IFG-ADA and 1.30 IGT). For coronary heart disease, a similar trend was found in the increasing risk of CVD for individuals with pre-diabetes, and no significant difference between the definition used (RR between 1.10 IFG-ADA and 1.28 HbA1c-NICE). Similarly, stroke individuals with pre-diabetes had constantly higher risks compared with NGT (RR between 1.06 IFG-ADA and 1.20 IGF), but not according to the HbA1c definitions. Regarding all-cause mortality, a higher risk was found for both the IFG and IGT definitions (RR between 1.13 IFG and 1.32 IGT), but not when it was defined with the HbA1c definition (see Table 2 ). 4 Most studies evaluated increased risks of progression to T2DM and CVD of pre-diabetes as dichotomous factor and differences between the definitions used. The Emerging Risk Factor Collaboration aimed to establish reliable estimates of associations of T2DM and fasting blood glucose concentration with fatal and non-fatal CVD. 2 To this end, data for 698,782 people (52,765 non-fatal or fatal vascular outcomes; 8.49 million person-years at risk) were included from 102 prospective studies. Results from this study showed that fasting blood glucose concentration was nonlinearly related to vascular risk, with no significant associations between 3.90 mmol/L and 5.59 mmol/L. Compared with fasting blood glucose concentrations of 3.90-5.59 mmol/L, the hazard ratios for coronary heart disease were 1.07 (0.9-1.2) for lower than 3.90 mmol/L; 1.11 (1.0-1.2) for 5.6-6.1 mmol/L; and 1.17 (1.1-1.3) for 6.10-6.99 mmol/L.
With regard to risk factors for people with pre-diabetes to develop CVD, the risk with concomitant hyperglycaemia is much higher in the presence of other risk factors, as shown already by the MrFIT study. 21 Also, sex differences have been reported. Large-scale meta-analyses have demonstrated that the excess risk of major cardiovascular complications associated with T2DM is substantially greater in women than men. 22, 23 The RR of incident coronary heart disease and stroke, respectively, associated with T2DM have been estimated to be 44% and 27% higher in women than in men. However, in the pre-diabetes state it is not that clear. Meta-analyses of individuals with IFG show no sex differences, while individuals with pre-diabetes based on post-OGTT show a higher risk for women than for men. It is thought that women have to undergo greater metabolic deterioration to develop T2DM compared with men, which is supported by studies that found that sex differences in risk factors already occur in the transition from NGT to prediabetes and diabetes. 24 During eight years of followup, women (aged 39-79 years) who progressed to T2DM showed relatively worse levels of total cholesterol, HDL cholesterol, triglycerides and diastolic blood pressure at baseline than men, compared with participants of the same sex who did not develop T2DM. 25 Consequently, progression from NGT to pre-diabetes (IFG) in women was associated with relatively greater endothelial dysfunction, a higher prevalence of hypertension and a greater degree of dysregulated fibrinolysis and coagulation than in male counterparts. 26 In addition to biological factors, sex differences in receiving guideline-recommended care might also be in place. For example, the 2012-2013 UK National Diabetes Audit reported women were 15% less likely than men to receive adequate care for the management of diabetes and prevention of its complications. 27 Thus, several risk factors are important to consider in preventing individuals progressing from pre-diabetes to T2DM and CVD. It is currently being debated whether individuals with pre-diabetes should be identified. The question is, how to stratify, which determinants are related to progression to T2DM and the development of CVD, and how can individuals with pre-diabetes be targeted for interventions aimed to reduce CVD risk. Results seem to indicate that hyperglycaemia is a risk factor of increasing magnitude with increasing levels. Therefore, dysglycaemia should be part of a total risk assessment.
Risk stratification for pre-diabetes
To facilitate targeted prevention of T2DM, many risk assessment models have been developed to identify people at high risk of developing T2DM or with undiagnosed T2DM. Collins et al. 28 performed a systematic review and identified 15 studies that developed a risk assessment model to predict prevalent (undiagnosed) T2DM. Many of these models included similar predictors such as age, sex, BMI, waist circumference, blood pressure and family history of T2DM. 28 Similarly, many models have been developed to predict future risk of T2DM. Abbasi et al. performed a systematic review to identify models predicting future risk of T2DM and validated all models in an external population. 29 This study showed that such risk assessment models generally performed very well to identify those at high risk to develop T2DM with C-statistics ranging from 0.7 to 0.8 for models based only on non-invasive information from questionnaires or a physical examination. Including a measure of glycaemic status in the models increased its performance to C-statistics ranging from 0.8 to 0.9. Similar to risk models for the prediction of T2DM, a substantial number of models have been developed to identify those with pre-diabetes. Barber et al. performed a systematic review and identified 18 models to predict pre-diabetes according to different criteria. 30 These models included similar predictors as those for T2DM. Their performance is good based on C-statistics of 0.7 and over in internal validation. However, external validation has rarely been performed for these models. To limit the demand of large-scale screening by means of blood tests, a commonly applied strategy is to start with a questionnaire to identify people at high risk of developing T2DM. Among risk scores, the Finnish Diabetes Risk Score (FINDRISC) has been validated not only in Finland but in many other countries. It is of value to detect IGT, relates to markers of insulin resistance and predicts CVD events and mortality. This questionnaire includes eight questions/items (age, BMI, waist circumference, physical activity, intake of fruit and vegetables, high blood pressure, history of high glucose value and family history of T2DM), which provide an assessment of the risk for T2DM during the following decade. Depending on the response to each question, a score (0-26) is set allocating the respondent to one of five risk categories, with a sensitivity of 78%, a specificity of 77% and a predictive value of a negative test of 99%. People with a high and very high risk can be recommended a laboratory-based evaluation of their glycaemic state. [31] [32] [33] Altogether, these studies indicate risk assessment models perform well to identify those at high risk to develop T2DM and could be used to target preventive interventions.
Management of pre-diabetes
Since a large proportion of people with pre-diabetes progress towards T2DM and pre-diabetes is also associated with an increased risk of vascular consequences of dysglycaemia, it is essential to prevent such progression by appropriate management. 34 Many studies thus far have, therefore, evaluated the effectiveness of lifestyle modification or medication to prevent T2DM in those at high risk. A recent meta-analysis summarized the results of randomized controlled trial assessing the efficacy of lifestyle or medical treatment to prevent T2DM in high-risk populations. 11 Although the trials consisted of heterogeneous populations, all trials were performed in adults identified as at risk of developing T2DM defined by the two-hour OGTT or a history of gestational diabetes. Therefore, a large proportion of participants could be considered as having pre-diabetes. These studies consistently show a considerable risk reduction in the occurrence of T2DM, with a RR of 0.69 (95% CI, 0.6-0.9) for studies with a duration of six months to two years, and a RR of 0.63 (95% CI, 0.5-0.7) for studies with a duration of 3-6 years. This results in a number needed to treat for lifestyle intervention of 12 (95% CI, [10] [11] [12] [13] [14] [15] .
Only four studies investigated the effect of treatment with metformin to prevent T2DM, and these studies showed a RR of 0.74 (95% CI, 0.6-0.8), resulting in a number needed to treat of 14 (95% CI, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Although effective, the two studies providing a direct comparison between lifestyle intervention and metformin showed that lifestyle intervention was more effective than metformin, albeit with a small difference in the Indian Diabetes Prevention Program (DPP). 35, 36 Because IGT and IFG have a different underlying pathophysiology, it is likely that efficacy of different preventive treatments may differ for these subgroups. IFG is characterized by reduced hepatic insulin sensitivity, beta-cell dysfunction and/or chronic low betacell mass, altered glucagon-like peptide-1 secretion and elevated glucagon secretion. Conversely, IGT is characterized by reduced peripheral insulin sensitivity with almost normal hepatic insulin sensitivity, while there is a progressive loss of beta-cell function, reduced secretion of glucose-dependent insulinotropic polypeptide and also elevated glucagon secretion. Combined IFG/IGT results in severe defects in both peripheral and hepatic insulin sensitivity and a progressive loss of beta-cell function. 37 A randomized controlled trial in people with IFG indeed showed that lifestyle intervention was ineffective among those with isolated IFG (RR 1.17; 95% CI, 0.5-2.7), while, among the participants with combined IFG/ IGT, lifestyle intervention reduced the risk of T2DM by 59% (95% CI, 0.2-0.7). 38 This result was supported by a lifestyle intervention trial reducing T2DM risk in people with IGT. 39 Indeed, in a secondary analysis of the DPP, the intervention with metformin was more effective in those with higher fasting glucose (6.1-6.9 mmol/l), with a 48% risk reduction, than among those with lower fasting glucose concentrations of 5.3-6.1 mmol/l (15% risk reduction). 40 Altogether, these results suggest that lifestyle intervention may be particularly effective for those with IGT.
Nevertheless, such interventions are only effective with long-term adherence to those behaviours. Therefore, several studies investigated the effect of the intervention with additional follow-up after termination of the trial. In a meta-analysis of these studies, Haw et al. 41 showed that at the end of the washout or follow-up periods, four studies showed that lifestyle intervention still resulted in a 28% risk reduction (RR 0.72; 95% CI, 0.6-0.9) with a mean follow-up of 7.2 years (range 5.7-9.4 years). Medication studies, on the other hand, showed no sustained risk reduction with a RR of 0.95 (95% CI, 0.8-1.1) with a shorter follow-up of, on average, 17 weeks (range 2-52 weeks). A thorough meta-analysis by LeBlanc et al. 42 showed there was limited evidence, to date, from larger trials that lifestyle interventions resulted in reduced prevalence of hypertension and use of CVD medications, compared with control conditions. Data were also limited and mixed for metabolic syndrome and 10-year CVD risk. Four medication trials reported on the use of lipid-lowering and antihypertensive medications, prevalence of metabolic syndrome and 10-year CVD risk score, with mixed results. 42 Altogether, these studies show that both lifestyle interventions and metformin are effective to prevent diabetes in high-risk individuals, although lifestyle interventions have stronger and more sustained effects. Indeed, a recent economical evaluation of lifestyle interventions and metformin to prevent the occurrence of T2DM showed that both low-and high-intensity interventions are cost-effective more than 71% of the time. Such interventions could reduce the incidence of T2DM by 3.5% over 50 years at 0.2-5.2% of the current diabetes budget in England. 43 Recent lifestyle recommendations from the European Society of Cardiology (ESC) guidelines on diabetes and prediabetes ad CVD report lifestyle changes as key for preventions of T2DM and CVD. However, still some gaps in knowledge remain, especially with regard to more tailored and adjusted advices for subgroups, such as elderly and different ethnic groups (Table 3 ).
Conclusion/future perspectives
In conclusion, the prevalence of pre-diabetes is high, but largely depends on the definition used. In addition, these different definitions also reflect differences in the underlying pathophysiology between mainly IGT and IFG. Irrespective of the definition used, people with pre-diabetes are at increased risk to develop T2DM and CVD. People diagnosed with pre-diabetes based on the ADA criteria will, on average, be at lower risk of T2DM and CVD than people with WHO-defined pre-diabetes. However, a substantial number (30%) of Table 3 . Lifestyle recommendations from the 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases.
Key message
Lifestyle changes are key to prevent T2DM and its CV complications.
Reduced calorie intake is recommended to lower excessive body weight in patients with T2DM. A Mediterranean diet supplemented with olive oil and/or nuts reduces the incidence of major CV events. Moderate-to-vigorous physical activity of 150 min/week is recommended for the prevention and control of T2DM. Gaps in the evidence Adherence to lifestyle changes. Ethnicity and diet. Effects of lifestyle measures on clinical outcomes. Lifestyle advice in different stages of life, e.g. in frail and elderly patients. Tailored exercise interventions in different ethnic groups and patient categories.
people diagnosed with pre-diabetes do not progress to T2DM. Therefore, much debate still exists about whom to target with diabetes prevention interventions and what parameter best predicts the progression to T2DM and risk of development to CVD. The risk of progression to T2DM or CVD does, however, depend on other risk factors such as sex, BMI and ethnicity. Despite this, lifestyle modification and medication are both effective in preventing the development of T2DM in those with pre-diabetes, although lifestyle modification has more sustainable effects. Furthermore, lifestyle modification is particularly effective in those with IGT. Altogether, risk stratification, using prediction models, in which the whole spectrum of glucose tolerance, including different types of pre-diabetes, is recommended. This way, targeted interventions per risk group can be designed. For prevention strategies in clinical practice, including the screening and treatment of individuals with pre-diabetes based on risk stratification, should be included in CVD risk management guidelines, beside a focus on dyslipidaemia and hypertension.
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